These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 36039025)
1. The LH endocrine profile in gonadotropin-releasing hormone analogue cycles. Janssens L; Roelant E; De Neubourg D Gynecol Endocrinol; 2022 Oct; 38(10):831-839. PubMed ID: 36039025 [No Abstract] [Full Text] [Related]
2. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Vuong TN; Phung HT; Ho MT Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882 [TBL] [Abstract][Full Text] [Related]
3. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels. Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817 [TBL] [Abstract][Full Text] [Related]
4. Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation. Popovic-Todorovic B; Santos-Ribeiro S; Drakopoulos P; De Vos M; Racca A; Mackens S; Thorrez Y; Verheyen G; Tournaye H; Quintero L; Blockeel C Hum Reprod; 2019 Oct; 34(10):2027-2035. PubMed ID: 31560740 [TBL] [Abstract][Full Text] [Related]
5. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women. Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355 [TBL] [Abstract][Full Text] [Related]
6. Recombinant human follicle-stimulating hormone stimulates multiple follicular growth, but minimal estrogen production in gonadotropin-releasing hormone antagonist-treated monkeys: examining the role of luteinizing hormone in follicular development and steroidogenesis. Karnitis VJ; Townson DH; Friedman CI; Danforth DR J Clin Endocrinol Metab; 1994 Jul; 79(1):91-7. PubMed ID: 8027261 [TBL] [Abstract][Full Text] [Related]
7. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159 [TBL] [Abstract][Full Text] [Related]
8. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger. Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700 [TBL] [Abstract][Full Text] [Related]
9. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285 [TBL] [Abstract][Full Text] [Related]
10. [Ovulation induction with pulsatile gonadotropin-releasing hormone and continuous human menopausal gonadotropin in polycystic ovarian disease]. Kuroda G Nihon Naibunpi Gakkai Zasshi; 1987 Mar; 63(3):247-59. PubMed ID: 3111899 [TBL] [Abstract][Full Text] [Related]
11. Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study. Strezsak V; Allignol A; Bühler K; Fischer R; Hubbard J; Longobardi S; Lispi M; Schertz J; Verpillat P Gynecol Obstet Invest; 2023; 88(4):214-225. PubMed ID: 37369184 [TBL] [Abstract][Full Text] [Related]
12. The role of gonadotropins in follicular development and their use in ovulation induction protocols for assisted reproduction. Zafeiriou S; Loutradis D; Michalas S Eur J Contracept Reprod Health Care; 2000 Jun; 5(2):157-67. PubMed ID: 10943580 [TBL] [Abstract][Full Text] [Related]
13. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization. Agrawal R; Conway GS; Engmann L; Bekir JS; Jacobs HS Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704 [TBL] [Abstract][Full Text] [Related]
14. Management of ovulation induction and intrauterine insemination in infertile patients with hypogonadotropic hypogonadism. Huseyin K; Berk B; Tolga K; Eser O; Ali G; Murat A J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):833-838. PubMed ID: 30930300 [TBL] [Abstract][Full Text] [Related]
15. The impact of LH-containing gonadotropin stimulation on euploidy rates in preimplantation embryos: antagonist cycles. Weghofer A; Munné S; Brannath W; Chen S; Barad D; Cohen J; Gleicher N Fertil Steril; 2009 Sep; 92(3):937-942. PubMed ID: 18774557 [TBL] [Abstract][Full Text] [Related]
16. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Kolibianakis EM; Albano C; Kahn J; Camus M; Tournaye H; Van Steirteghem AC; Devroey P Fertil Steril; 2003 Apr; 79(4):873-80. PubMed ID: 12749423 [TBL] [Abstract][Full Text] [Related]
17. [Effect of concentration of circulating luteinizing hormone in late-follicle phase on the outcome of in vitro fertilization for normogonadotrophic women]. Sun H; Hu Y; Wang B; Chen Q; Zhang N; Chen H; Wang J; Xu Z Zhonghua Nan Ke Xue; 2004 Dec; 10(12):912-5. PubMed ID: 15638021 [TBL] [Abstract][Full Text] [Related]
18. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010 [TBL] [Abstract][Full Text] [Related]
19. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Tavaniotou A; Albano C; Smitz J; Devroey P Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214 [TBL] [Abstract][Full Text] [Related]
20. Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. II. Comparison of hMG and recombinant FSH. Duijkers IJ; Willemsen WN; Hollanders HM; Hamilton CJ; Thomas CM; Vemer HM Int J Fertil Womens Med; 1997; 42(6):431-5. PubMed ID: 9459089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]